Granulomatous disease: is it a nuisance or an asset during PET/computed tomography evaluation of lung cancers?

Nuclear Medicine Communications

Volumn 29, Issue 7, 2008, Pages 623-627

  Chundru, Surya ^a   Wong, Ching yee Oliver ^a   Wu, Dafang ^a   Balon, Helena ^a   Palka, Jane ^a   Chang, Chih Yung ^a   Gaskill, Marianne ^b   Cheng, Cheng Yi ^b   Huang, Wen Sheng ^b   Fink Bennett, Darlene ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Granulomatous disease; Lung cancers; PET computed tomography

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC GRANULOMATOUS DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMAGE SUBTRACTION; LUNG COIN LESION; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISCRIMINANT ANALYSIS; EVALUATION; GOLD STANDARD; GRANULOMATOSIS; HISTOPATHOLOGY; LUNG BIOPSY; LUNG CALCIFICATION; LUNG CANCER; LUNG NODULE; LYMPH NODE; LYMPHATIC DRAINAGE; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ADULT; AGED; AGED, 80 AND OVER; COIN LESION, PULMONARY; DIAGNOSIS, DIFFERENTIAL; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

EID: 49649111706     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282fdc979     Document Type: Article

References (22)

1. Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med 2006; 47:451-469.
2. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and pet. J Nucl Med 1996; 37:943-948.
3. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084.
4. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31:1927-1932.
5. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995; 110:130-139.
6. Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Resp J 1996; 9:410-414.
7. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109:982-988.
8. Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM, Hoffman JM, Wolfe WG, Coleman RE. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997; 202:435-439.
9. Hübner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S, Dickey J. Differentiating benign from malignant lung lesions using “quantitative” parameters of FDG PET images. Clin Nucl Med 1996; 21:941-949.
10. Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med 1995; 20:293-298.
11. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999; 117:719-727.
12. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, Goodman PC. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490.
13. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, et al. Fluorodeoxyglucose positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996; 153:417-421.
14. Croft DR, Trapp J, Kernstine K, Kirchner P, MullanB, GalvinJ, et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 2002; 36:297-301.
15. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000; 216:117-121.
16. Wilkinson MD, Fulham MJ, McCaughan BC, Constable CJ. Invasive aspergillosis mimicking stage IIIA non-small-cell lung cancer on FDG positron emission tomography. Clin Nucl Med 2003; 28:234-235.
17. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649.
18. Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchoalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002; 29:1166-1173.
19. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998; 170:1369-1373.
20. Sharma A, Fidias P, Hayman LA, Loomis SL, Taber KH, Aquino SL. Patterns of lymphadenopathy in thoracic malignancies. Radiographics 2004; 24:419-434.
21. Wong CO, Hill J, Welsh R, Chmielewski G, Ravikrishnan KP, Yang YW, et al. Use of intelligent computer search for the patterns of abnormal lymphatic uptake by F-18 FDG PET in primary lung cancers. J Med Sci 2006; 26:199-204.
22. Grills IS, Yan D, Black QC, Wong CY, Martinez AA, Kestin LL. Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67:709-719.